AMA 2023 Interim: American Medical Association Interim Meeting

(UroToday.com) Through UroToday’s Health Policy Center of Excellence, we aim to inform the urologic community about pivotal health policy issues that affect our patients, practice, and profession. Despite urology being a smaller specialty within the broader healthcare field, the perspective of the urologist is critical.

The American Medical Association (AMA) is the largest and most influential body of organized medicine. Through a unified voice, physicians have the ability to exert influence over policy changes that will impact healthcare through adopting AMA policy. The AMA continually addresses issues related to the practice of medicine, including public health, scope of practice, diversity, equity & inclusion, and legislative advocacy.

Twice a year, the AMA convenes to draft, discuss, and pass policy that shapes the organization’s advocacy and legislative priorities. These policies, entitled “resolutions,” are crafted using a democratic process within the House of Delegates, the policy-making arm of the AMA. Any AMA member can draft a resolution to adopt as AMA policy. Two urologic organizations, the American Urological Association (AUA) and the American Association of Clinical Urologists (AACU) hold seats in the policy-making arm of the AMA, the House of Delegates. This week, the House of Delegates will be meeting in National Harbor, Maryland.

This week, we will be providing coverage of topics of interest to the urologic community including oversight and training of non-physician practitioners, recognizing specialty physician certifications, loan forgiveness for rural health physicians, drug shortages, and prior authorization. The meeting will also provide educational content regarding various healthcare issues such as healthcare advocacy, equity in healthcare, and reducing burnout/improving wellness. Please follow along with our meeting coverage to stay up to date on important policy developments throughout the AMA’s Interim meeting!

Written by: Ruchika Talwar, MD, Urologic Oncology Fellow, Vanderbilt University Medical Center during the 2023 AMA Interim Meeting, Nov 10 to Nov 14